Stay updated on Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision history shows an update from v3.2.0 to v3.3.2, a minor metadata change that does not affect study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedThe site-wide funding status notice about government operations was removed from this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedThe Study Details page for NCT05155085 appears unchanged between the two screenshots, with no visible edits to study design, eligibility criteria, outcomes, or site list.SummaryDifference0.3%

- Check71 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content, indicating a restructuring and possible narrowing of the domain coverage.SummaryDifference0.4%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top link was removed; no substantive changes to core content.SummaryDifference0.2%

Stay in the know with updates to Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.